| Assessment Status | Rapid Review Complete |
| HTA ID | 22062 |
| Drug | Macimorelin acetate |
| Brand | Ghryvelin® |
| Indication | For the diagnosis of growth hormone deficiency (GHD) in adults. |
| Assessment Process | |
| Rapid review commissioned | 30/08/2022 |
| Rapid review completed | 04/10/2022 |
| Rapid review outcome | The NCPE recommends that macimorelin acetate (Ghryvelin®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
